Agenda: Next Generation Cell Therapies: Combined Analytics & Cryopreserved Starting Materials

11:00 am Opening Remarks

11:05 am Providing Consistency for Apheresis Starting Material for Autologous CAR-T Manufacturing through Cryopreservation

  • Daniel Ciccone CAR-T Cell Collection Operations Manager, Janssen Pharmaceuticals

Synopsis

  • Use of cryopreservation to allow for flexibility in logistics/scheduling
  • Bringing consistency to starting material across variable patient populations through a standard cryopreservation process

11:25 am Product Development for Cryopreserved Starting Materials

Synopsis

  • Optimization of critical quality attributes for cryopreserved starting materials for early phase trials
  • Strategies for cryopreserving starting materials for allogeneic and autologous CGT products

11:45 am How the Right Starting Materials Can Deliver a Higher Probability of Attaining Cell & Gene Therapy Manufacturing Success

  • Dominic Clarke Chief Technical Officer of
    Cell & Gene Therapies, Discovery Life Sciences

Synopsis

  • Outline how characterized donor source materials can impact consistency from process development to manufacturing
  • Strategies for building efficiencies and alleviate bottlenecks by implementing cryopreserved leukapheresis
  • Requirements to delivering a sustainable starting material supply chain for large-scale allogeneic therapies

12:05 pm Live Audience Q&A

  • Dominic Clarke Chief Technical Officer of
    Cell & Gene Therapies, Discovery Life Sciences
  • Daniel Ciccone CAR-T Cell Collection Operations Manager, Janssen Pharmaceuticals
  • Phillip Eckels Head of Operations, K2 Biolabs

12:30 pm End of Discovery Life Sciences Webinar